化瘀降浊合剂干预代谢综合征的疗效评价及其对部分致动脉粥样硬化因子的影响
|
摘要
本论文包括文献综述、临床研究和实验研究三部分内容。
在文献综述部分系统回顾了近20年来国内外中西医在代谢综合征(MS)的临床和基础研究方面的进展情况。比较全面地反映了当今对MS流行病学、诊断、评价方法、发病机制、临床危害和干预措施等方面的研究现状和发展趋势,总结了现代中医药学家对MS在病因病机、分证论治、中医药干预和中药作用机制研究等方面的进展情况,简要分析了目前研究中存在的问题和薄弱环节,展望了中医药干预MS的发展方向和可能的切入点。
在临床研究部分观察了化瘀降浊合剂治疗代谢综合征的疗效及其对部分致动脉粥样硬化危险因子的影响。本研究选择符合2005年国际糖尿病联盟定义且辨证为湿浊血瘀证候的MS患者70名,随机分为中药治疗组35例,西药对照组35例,中药治疗组给予化瘀降浊合剂治疗,对照组给予马来酸罗格列酮治疗,连续治疗8周。治疗前后分别观察了患者的临床症状、体重指数(BMI)、腰臀比(WHR)、血糖、血脂、血压、胰岛素作用指数(IAI)、胰岛素抵抗指数(HOMA-IR)、超敏C反应蛋白(hs-CRP)、同型半胱氨酸、纤维蛋白原、尿白蛋白排泄率、肱动脉舒张功能和不良反应。结果显示,化瘀降浊合剂可有效改善MS患者的临床症状(P<0.05),中医证候疗效总有效率为78.79%,明显优于对照组(P<0.05)。对轻中度高血糖和脂代谢紊乱有明显的改善作用(P<0.05),与马来酸罗格列酮的作用相似(P>0.05)。化瘀降浊合剂与马来酸罗格列酮对血压都有轻度改善作用,同时化瘀降浊合剂可以降低脉压差,与治疗前比较有统计学差异(P<0.05)。治疗后两组的IAI均有提高,HOMA-IR均有下降,与治疗前比较有统计学差异(P<0.05),而组间比较无统计学差异(P>0.05),提示化瘀降浊合剂具有与马来酸罗格列酮相近的改善胰岛素抵抗的作用。另外,化瘀降浊合剂可显著降低hs-CRP、同型半胱氨酸、纤维蛋白原、尿白蛋白排泄率,改善肱动脉舒张功能,对这些致动脉粥样硬化危险因子的改善作用提示化瘀降浊合剂可能具有预防或延缓动脉粥样硬化发生和进展的作用。在观察期内未发现中药的明显不良反应及肝肾副作用。
在实验研究中采用高脂高盐饲料喂养的方法建立了胰岛素抵抗大鼠模型。观察了化瘀降浊合剂对胰岛素抵抗大鼠体重、糖脂代谢、血压、胰岛素敏感性、血清肿瘤坏死因子-α(TNF-α)和脂联素等影响以及脂肪组织中TNF-αmRNA和脂联素mRNA表达水平的影响。结果显示,化瘀降浊合剂可显著抑制胰岛素抵抗大鼠体重的增长,明显优于西药组(P<0.05),中药组大鼠的体重增长速度与空白对照组相近;明显改善糖脂代谢紊乱和胰岛素敏感性(P<0.05),与罗格列酮作用相近(P>0.05);轻度降低血压,但无统计学差异;抑制脂肪组织TNF-αmRNA的表达而降低血清TNF-α水平;促进脂肪组织脂联素mRNA的表达而升高血清脂联素水平。综合以上研究结果认为,化瘀降浊合剂具有改善糖脂代谢和胰岛素敏感性的作用,具有明显的抗炎作用和升高血管保护因子脂联素的作用,这些作用在改善胰岛素抵抗,纠正代谢紊乱的同时有利于血管内皮的保护,可预防或延缓动脉粥样硬化的发生和发展。
My thesis includes three parts: literature summarization, clinical observation and experimental research.
The part of literature summarization reviews the progress of clinical and experimental research on treating metabolic syndrome (MS), including the aspects of Western Medicine and Traditional Chinese Medicine (TCM). This part reflects the status quo of researches on epidemiology, diagnosis, evaluation criteria, pathogenesis, clinical features and intervention. It also summarizes the knowledge of scholars of TCM on the etiology, pathogenesis, differentiation of TCM syndrome, and TCM intervention and mechanism. Unsolved problems, weak points and possible solution of researches on MS are also analyzed in this part.
Clinical research was performed to observe the clinical efficiency of HuaYu JiangZhuo Mixture (HYJZM) on MS and its effect on pro-atherosclerosis risk factors. 70 MS patients conforming to 2005 definition given by International Diabetes Federation (IDF) were randomly divided into two groups: HYJZM-treated group (n=35) and western medicine- treated group (n=35). The patients were identified as the syndrome of blood stasis and phlegm-dampness and treated with HYJZM or Rosiglitazone for 8 weeks. Clinical symptom, body mass index (BMI), waist-hip ratio (WHR), fasting plasma glucose (FPG), two hour plasma glucose (2hPG), blood pressure (BP), total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), insulin action index (IAI), high sensitive C reactive protein (hs-CRP), homocysteine (Hcy), fibrinogen, urinary albumin excretion rate (UAER), brachial artery dilation and adverse reaction were observed before and after treatment for the two groups. Results showed that clinical manifestation of HYJZM-treated group was improved significantly (P<0.05). The total efficiency of HYJZM on TCM syndrome was as high as 78.79%, which was higher than that of Rosiglitazone- treated group (P<0.05). Hyperglycemia and lipid metabolism disturbance were improved in both HYJZM- and Rosiglitazone-treated groups (P<0.05) and there was no statistical significance between these two groups. BP in both groups was slightly lowered, showing no difference when compared with that before treatment. Pulse pressure was decreased in HYJZM-treated group, which was lower than that before treatment (P<0.05). IAI was augmented in both groups, suggesting that HYJZM and Rosiglitazone have similar improving effects on insulin resistance. The plasma levels of hs-CRP, Hcy, fibrinogen, and UAER were decreased and brachial artery dilation was improved when treated with HYJZM. These data support the notion that HYJZM may protest against the process of atherosclerosis through controlling pro-atherosclerosis risk factors. No obvious adverse reaction and side effect were observed in HYJZM-treated group.
Rat insulin resistance model was established through feeding a high-fat-salt diet. The effects of HYJZM on body weight, glucose and lipid metabolism, BP, IAI were observed. Serum levels and mRNA expressions in adipose tissue of TNF-αand adiponectin were also investigated. Results showed that HYJZM treatment suppressed the increase of body weight significantly, which was better than Rosiglitazone treatment. HYJZM and Rosiglitazone had similar improving effects on glucose and lipid metabolism disturbance and insulin sensitivity. BP was lowered slightly in HYJZM-treated group (P>0.05). HYJZM suppressed the mRNA expression of TNF-αin adipose tissue and lowered the serum level of TNF-α. Furthermore, the mRNA expression in adipose tissue and serum level of adiponectin were promoted in HYJZM-treated group. Taken together, HYJZM has improving effect on glucose and lipid metabolism and insulin sensitivity. HYJZM treatment augments adiponectin level and exerts anti-inflammatory effect. These results suggest that HYJZM may prevent the development and progress of atherosclerosis through protecting the function of vascular endothelia.
在文献综述部分系统回顾了近20年来国内外中西医在代谢综合征(MS)的临床和基础研究方面的进展情况。比较全面地反映了当今对MS流行病学、诊断、评价方法、发病机制、临床危害和干预措施等方面的研究现状和发展趋势,总结了现代中医药学家对MS在病因病机、分证论治、中医药干预和中药作用机制研究等方面的进展情况,简要分析了目前研究中存在的问题和薄弱环节,展望了中医药干预MS的发展方向和可能的切入点。
在临床研究部分观察了化瘀降浊合剂治疗代谢综合征的疗效及其对部分致动脉粥样硬化危险因子的影响。本研究选择符合2005年国际糖尿病联盟定义且辨证为湿浊血瘀证候的MS患者70名,随机分为中药治疗组35例,西药对照组35例,中药治疗组给予化瘀降浊合剂治疗,对照组给予马来酸罗格列酮治疗,连续治疗8周。治疗前后分别观察了患者的临床症状、体重指数(BMI)、腰臀比(WHR)、血糖、血脂、血压、胰岛素作用指数(IAI)、胰岛素抵抗指数(HOMA-IR)、超敏C反应蛋白(hs-CRP)、同型半胱氨酸、纤维蛋白原、尿白蛋白排泄率、肱动脉舒张功能和不良反应。结果显示,化瘀降浊合剂可有效改善MS患者的临床症状(P<0.05),中医证候疗效总有效率为78.79%,明显优于对照组(P<0.05)。对轻中度高血糖和脂代谢紊乱有明显的改善作用(P<0.05),与马来酸罗格列酮的作用相似(P>0.05)。化瘀降浊合剂与马来酸罗格列酮对血压都有轻度改善作用,同时化瘀降浊合剂可以降低脉压差,与治疗前比较有统计学差异(P<0.05)。治疗后两组的IAI均有提高,HOMA-IR均有下降,与治疗前比较有统计学差异(P<0.05),而组间比较无统计学差异(P>0.05),提示化瘀降浊合剂具有与马来酸罗格列酮相近的改善胰岛素抵抗的作用。另外,化瘀降浊合剂可显著降低hs-CRP、同型半胱氨酸、纤维蛋白原、尿白蛋白排泄率,改善肱动脉舒张功能,对这些致动脉粥样硬化危险因子的改善作用提示化瘀降浊合剂可能具有预防或延缓动脉粥样硬化发生和进展的作用。在观察期内未发现中药的明显不良反应及肝肾副作用。
在实验研究中采用高脂高盐饲料喂养的方法建立了胰岛素抵抗大鼠模型。观察了化瘀降浊合剂对胰岛素抵抗大鼠体重、糖脂代谢、血压、胰岛素敏感性、血清肿瘤坏死因子-α(TNF-α)和脂联素等影响以及脂肪组织中TNF-αmRNA和脂联素mRNA表达水平的影响。结果显示,化瘀降浊合剂可显著抑制胰岛素抵抗大鼠体重的增长,明显优于西药组(P<0.05),中药组大鼠的体重增长速度与空白对照组相近;明显改善糖脂代谢紊乱和胰岛素敏感性(P<0.05),与罗格列酮作用相近(P>0.05);轻度降低血压,但无统计学差异;抑制脂肪组织TNF-αmRNA的表达而降低血清TNF-α水平;促进脂肪组织脂联素mRNA的表达而升高血清脂联素水平。综合以上研究结果认为,化瘀降浊合剂具有改善糖脂代谢和胰岛素敏感性的作用,具有明显的抗炎作用和升高血管保护因子脂联素的作用,这些作用在改善胰岛素抵抗,纠正代谢紊乱的同时有利于血管内皮的保护,可预防或延缓动脉粥样硬化的发生和发展。
My thesis includes three parts: literature summarization, clinical observation and experimental research.
The part of literature summarization reviews the progress of clinical and experimental research on treating metabolic syndrome (MS), including the aspects of Western Medicine and Traditional Chinese Medicine (TCM). This part reflects the status quo of researches on epidemiology, diagnosis, evaluation criteria, pathogenesis, clinical features and intervention. It also summarizes the knowledge of scholars of TCM on the etiology, pathogenesis, differentiation of TCM syndrome, and TCM intervention and mechanism. Unsolved problems, weak points and possible solution of researches on MS are also analyzed in this part.
Clinical research was performed to observe the clinical efficiency of HuaYu JiangZhuo Mixture (HYJZM) on MS and its effect on pro-atherosclerosis risk factors. 70 MS patients conforming to 2005 definition given by International Diabetes Federation (IDF) were randomly divided into two groups: HYJZM-treated group (n=35) and western medicine- treated group (n=35). The patients were identified as the syndrome of blood stasis and phlegm-dampness and treated with HYJZM or Rosiglitazone for 8 weeks. Clinical symptom, body mass index (BMI), waist-hip ratio (WHR), fasting plasma glucose (FPG), two hour plasma glucose (2hPG), blood pressure (BP), total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), insulin action index (IAI), high sensitive C reactive protein (hs-CRP), homocysteine (Hcy), fibrinogen, urinary albumin excretion rate (UAER), brachial artery dilation and adverse reaction were observed before and after treatment for the two groups. Results showed that clinical manifestation of HYJZM-treated group was improved significantly (P<0.05). The total efficiency of HYJZM on TCM syndrome was as high as 78.79%, which was higher than that of Rosiglitazone- treated group (P<0.05). Hyperglycemia and lipid metabolism disturbance were improved in both HYJZM- and Rosiglitazone-treated groups (P<0.05) and there was no statistical significance between these two groups. BP in both groups was slightly lowered, showing no difference when compared with that before treatment. Pulse pressure was decreased in HYJZM-treated group, which was lower than that before treatment (P<0.05). IAI was augmented in both groups, suggesting that HYJZM and Rosiglitazone have similar improving effects on insulin resistance. The plasma levels of hs-CRP, Hcy, fibrinogen, and UAER were decreased and brachial artery dilation was improved when treated with HYJZM. These data support the notion that HYJZM may protest against the process of atherosclerosis through controlling pro-atherosclerosis risk factors. No obvious adverse reaction and side effect were observed in HYJZM-treated group.
Rat insulin resistance model was established through feeding a high-fat-salt diet. The effects of HYJZM on body weight, glucose and lipid metabolism, BP, IAI were observed. Serum levels and mRNA expressions in adipose tissue of TNF-αand adiponectin were also investigated. Results showed that HYJZM treatment suppressed the increase of body weight significantly, which was better than Rosiglitazone treatment. HYJZM and Rosiglitazone had similar improving effects on glucose and lipid metabolism disturbance and insulin sensitivity. BP was lowered slightly in HYJZM-treated group (P>0.05). HYJZM suppressed the mRNA expression of TNF-αin adipose tissue and lowered the serum level of TNF-α. Furthermore, the mRNA expression in adipose tissue and serum level of adiponectin were promoted in HYJZM-treated group. Taken together, HYJZM has improving effect on glucose and lipid metabolism and insulin sensitivity. HYJZM treatment augments adiponectin level and exerts anti-inflammatory effect. These results suggest that HYJZM may prevent the development and progress of atherosclerosis through protecting the function of vascular endothelia.
引文
1 张志玲, 李惠林, 张黎群, 等. 活血降糖饮治疗代谢综合征 30 例疗效观察. 中医药临床杂志, 2004, 16(4): 327-328.
2 赵天豫, 段军, 仝小林. 中医治疗糖尿病的新思路. 光明中医, 2002, 17(5): 12-13.
3 李东晓. 痰与代谢综合征. 中国中医基础医学杂志, 2005, 11(2): 144-145.
4 柴可夫, 王亚丽. 从痰瘀论治胰岛素抵抗. 中华中医药杂志, 2005, 20(9): 542-543.
5 袁肇凯, 黄献平, 简亚平, 等. 高脂血症痰瘀证候与胰岛素抵抗的关系. 中国医药学报, 2003, 18(8): 468-470.
6 徐远. 中医治疗代谢综合征的思路与方法. 中医杂志, 2003, 44(4): 301-302.
7 刘承琴, 赵建群. 2 型糖尿病胰岛素抵抗重视从脾论治的思路. 新中医, 2003, 35(9): 28-29.
8 李锡杰, 刘志龙. 论从脾论治代谢综合征. 中医药导报, 2006, 12(4): 9-11.
9 王智明. 胰岛素抵抗从肝论治的探讨. 光明中医, 2003, (18)6: 13-14.
10 王德玉, 徐志瑛. 论肝与代谢综合征. 浙江中西医结合杂志, 2004, 14(1): 23-24.
11 董卫. 综合治疗胰岛素抵抗综合征 56 例. 山西中医, 2004, 20(6): 17.
12 杨文军, 庄严. 胰岛素抵抗综合征辨治初探. 山东中医药大学学报, 2002, 26(4): 275-276.
13 张德贵, 贺建丽. 调肝滋肾法治疗胰岛素抵抗及其相关性疾病之临证与探讨. 光明中医, 2002, 17(4): 26-27.
14 吴深涛. 对胰岛素抵抗宜用益肾化瘀、疏利少阳法. 中医杂志, 2001, 42(6): 332-333.
15 张玉金, 张文艺. 高血压病辨证分型和胰岛素抵抗关系的探讨. 河南中医, 2001, 21(1): 36.
16 梁兴伦, 韩明向. 胰岛素抵抗模型大鼠的中医证候研究. 中国中西医结合杂志, 2001, 21(7): 528-530.
17 朱章志, 熊曼琪. Ⅱ型糖尿病患者不同证型红细胞胰岛素受体缺陷的观察. 中国中西医结合杂志, 1995, 15(5): 266-268.
18 周国英, 武雪萍, 衡先培, 等. Ⅱ型糖尿病气阴两虚证与胰岛素抵抗的相关性研究. 福建中医药, 2000, 31(2): 7-8.
19 于顾然, 贺燕勤, 郭云庚, 等. 冠心病中医证型与胰岛素抵抗、脂质及红细胞膜 ATP酶关系的临床研究. 中医杂志, 2000, 41(2): 111-112.
20 常宗范, 冯奕超. 胰岛素抵抗的中医辨证论治. 吉林中医药, 2001, (3): 54-55.
21 陈思兰, 林兰, 楚晓燕. Ⅱ型糖尿病中医辨证分型与胰岛素抵抗的相关性分析. 中国中医药信息杂志, 2001, 8(6): 49-51.
22 刘惠文, 张铁志, 李光伟, 等. 高血压病患者胰岛素抵抗与中医辨证分型的相关性研究. 中国中西医结合杂志, 1999, 19(4): 200.
23 李秋炎, 贾太平, 赵展荣, 等. Ⅱ型糖尿病患者中医辨证分型与胰岛 β 细胞功能关系的研究. 中医杂志, 1998, 39(7): 428.
24 黎学松, 岑永庄, 梁干雄, 等. Ⅱ型糖尿病中医分型与胰岛素抵抗相关性分析. 辽宁中医杂志, 1998, 25(8): 345.
25 王喜瑛, 郑姜卿, 吕绍光. 36 例 2 型糖尿病中医不同证型的胰岛素抵抗观察. 福建中医学院学报, 2003, 13(6): 8-9.
26 王琦, 李英帅. 中医对代谢综合征的认识及辨治探讨(下). 浙江中医杂志, 2006, 41(11): 623-625.
27 倪艳霞, 刘安强, 高云峰, 等. 黄连素治疗Ⅱ型糖尿病 60 例疗效观察及实验研究. 中西医结合杂志, 1988, 8(12): 711-712.
28 陈其明, 谢明智. 黄连及小檗碱降血糖的研究. 药学学报, 1986, 21(6): 401.
29 赵荣华. 518 个糖尿病处方统计分析. 云南中医学院学报, 20(2): 20-23.
30 李志荣. 黄芪多糖冲剂治疗Ⅱ型糖尿病的临床研究. 山西医药, 1995, 11(11): 16.
31 黄立武, 钱海凌, 孙淑荣, 等. 黄芪注射液对老年脑梗死恢复期胰岛素抵抗的影响. 中国康复理论与实践, 2004, 10(1): 55-56.
32 黄春玲, 吕玉萍. 黄芪辅助治疗 2 型糖尿病对胰岛素抵抗的影响. 中国中西医结合杂志, 2003, 23(10): 779-780.
33 黄琦, 许家鸾. 麦冬多糖对 2 型糖尿病血糖及胰岛素抵抗的影响. 浙江中西医结合杂志, 2002, 12(2): 81-82.
34 于志清. 纯单黄酮甙碘-胰岛素与脂肪细胞结合的影响. 广西医学院学报, 1980(1): 22.
35 潘玲, 冯全生. 八味丸方药对代谢综合征患者治疗效应的临床观察. 四川生理科学杂志 2005, 27(2): 87-91.
36 管弦, 黄菲, 吴纪祖, 等. 六味地黄丸银杏叶片对早期 2 型糖尿病胰岛素抵抗与脂毒性的影响. 辽宁中医杂志, 2006, 33(11): 1423-1426.
37 李莉芬, 吴玉红. 金芪降糖片治疗 2 型糖尿病胰岛素抵抗患者的观察. 天津医药, 2006, 34(9): 654-656.
38 陈苹, 朱章志, 郎江明, 等. 益气养阴活血通腑法治疗 2 型糖尿病磺脲类药继发性失效的临床观察. 中国中西医结合杂志, 2004, 11(7): 585-588.
39 陈维铭, 王馨然. 半夏白术天麻汤对单纯性肥胖患者胰岛素抵抗的影响. 现代中西医结合杂志, 2004, 13(2): 351-353.
40 喻红, 邹先智. 地黄饮子对改善糖尿病胰岛素抵抗的疗效观察. 湖南中医药导报, 2001, 7(1): 19.
41 仝小林, 柳红芳, 朴信映, 等. 开郁清胃颗粒治疗Ⅱ型糖尿病胰岛素抵抗的临床研究. 实用中医内科杂志, 2001, 15(2): 10-11.
42 袁肇凯, 黄献平, 田松, 等. 养心通脉片对胰岛素抵抗综合征血脂及甲襞微循环的影响. 湖南中医学院学报, 2003, 23(4): 35-38.
43 黄献平, 袁肇凯, 卢芳国, 等. 养心通脉片对胰岛素抵抗综合征病人红细胞胰岛素受体的影响. 中西医结合心脑血管病杂志, 2003, 1(7): 373-375.
44 黄献平, 袁肇凯, 卢芳国, 等. 养心通脉片对胰岛素抵抗综合征患者红细胞膜的影响. 中国中医药信息杂志. 2003, 10(12): 12-14.
45 卢芳国, 袁肇凯, 黄献平, 等. 养心通脉片对胰岛素抵抗综合征外周血单核细胞C-myc 和 PDGF-A mRNA 表达的影响. 中西医结合心脑血管病杂志. 2003, 1(8): 442-444.
46 刘英华, 陈春梅, 赖育红, 等. 通心络改善糖尿病冠心病患者胰岛素抵抗的观察研究. 天津中医药, 2006, 23(4): 282-283.
47 钱秋海, 庄乾竹. 愈胰饮治疗胰岛素抵抗综合征的临床研究. 中国中医药信息杂志, 2002, 9(7): 12-14.
48 郭志华, 袁肇凯, 王东生. 四泰片治疗高血压病胰岛素抵抗的临床研究. 中成药, 2004, 26(2): 162-164.
49 安其, 李朝敏, 程斌. 安一胶囊治疗胰岛素抵抗综合征的临床观察. 成都中医药大学学报, 2003, 25(1): 10-12.
50 刘宪俊, 杨叔禹, 陈弼沧, 等. 平糖胶囊对气阴两虚型 2 型糖尿病患者胰岛素抵抗干预的研究. 福建中医药, 2006, 37(4): 3-5.
51 宋镇星 . 调谢胶囊治疗代谢综合征疗效观察 . 辽宁中医杂志, 2006, 33(10): 1294-1295.
52 戴飞跃, 黄保民, 唐晨光, 等. 福寿降糖饮治疗 2 型糖尿病胰岛素抵抗的临床观察. 中医药学刊. 2006, 24(8): 1497-1498.
53 徐云生, 杜丙会. 中西医结合治疗 X 综合征 30 例. 山东中医杂志, 1998, 17(5): 224.
54 姜淼. 三黄安消胶囊治疗 2 型糖尿病及改善胰岛素抵抗作用的临床研究. 新中医, 2006, 38(1): 28-30.
55 杨文军, 郭宝荣, 赵泉霖. 中药配合口服降糖药对 2 型糖尿病患者胰岛素抵抗及微量白蛋白尿的影响. 山东中医药大学学报, 2003, 27(4): 285-286.
56 邓德强. 培土活血解毒法治疗 2 型糖尿病及胰岛素抵抗的临床研究. 新中医, 2003, 35(4): 35-37.
57 卢晓琳. 益气养阴活血通腑法治疗胰岛素抵抗综合征 52 例. 河北中医, 2003, 25(4): 270-271.
58 张慧, 郭宏敏. 中药养阴和瘀方对老年代谢综合征胰岛素抵抗及高凝血症的干预作用的研究. 中国老年保健医学杂志, 2006, 4(3): 50-52.
59 刘振杰. 扶脾抑胃法治疗胰岛素抵抗性糖尿病. 湖北中医杂志, 2006, 28(10): 13-14.
60 薛青, 张桦, 李中和, 等. 益肾疏肝泄毒祛瘀法改善 2 型糖尿病早期肾病胰岛素抵抗的研究. 中药材, 2006, 29(10): 1120-1122.
61 刘志诚, 孙凤岷, 朱苗花, 等. 针灸对非胰岛素依赖性糖尿病胰岛素抵抗的影响. 上海针灸杂志, 2000, 19(1): 5-7.
62 谌剑飞, 马雅玲, 蔡绍华, 等. 针刺对糖尿病的抗凝与逆转胰岛素抵抗作用. 上海针灸杂志, 2001, 20(4): 5-7.
63 唐胜修. 头穴对中风后遗症患者胰岛素抵抗的调整作用研究. 安徽中医临床杂志,2002, 14(3): 164-165.
64 魏群利, 刘志诚. 针刺配合耳穴压籽治疗 2 型糖尿病(肥胖型)67 例. 安徽中医学院学报, 2002, 21(3): 34-37.
65 秦福兰, 贾杰, 郭学军. 针刺和运动疗法对 2 型糖尿病的疗效观察. 中国针灸, 2002, 22(9): 579-581.
66 张智龙, 薛莉, 吉学群, 等. 针刺对 2 型糖尿病胰岛素抵抗影响的临床研究. 中国针灸, 2002, 22(11): 723-725.
67 胡葵, 李嘉, 刘志诚. 针灸治疗肥胖型 2 型糖尿病的临床研究. 上海针灸杂志, 2001, 20(4): 8-10.
68 高从容, 张家庆, 黄庆玲. 黄连素增加胰岛素抵抗大鼠模型胰岛素敏感性的研究. 中国中西医结合杂志, 1997, 17(8): 162.
69 陆灏, 叶伟成, 丁学屏. 黄连素对实验大鼠胰岛素抵抗的影响. 辽宁中医学院学报, 2002, 4(4): 259-260.
70 谢宗长, 钱振坤, 柳重威. 人参抗实验性糖尿病大鼠脂质过氧化损伤的研究. 中国中西医结合杂志, 1993, 13(5): 289-290.
71 胡翠华, 徐华丽, 于晓风, 等. 人参二醇组皂苷对实验性 2 型糖尿病大鼠血糖及血脂代谢的影响. 吉林大学学报(医学版), 2006, 32(6): 1004-1008.
72 刘永玉, 毛良, 莫启忠, 等. 实验性 2 型糖尿病大鼠的胰岛素抵抗性. 中国病理生理杂志, 1991, 7(4): 422-425.
73 祁忠华, 林善镁, 黄宇峰, 等. 黄芪改善糖尿病肾病早期血流动力学异常的研究. 中国糖尿病杂志, 1999, 7(3): 147-149.
74 鲁瑾, 邹大进, 张家庆. 黄芪预防肿瘤坏死因子-α 所致胰岛素抵抗. 中国中西医结合杂志, 1999, 19(7): 420-422.
75 金椿, 戴瑞鸿, 周峰, 等. 黄芪对冠心病患者红细胞内钠含量和钠转运的影响. 中西医结合杂志, 1991(11): 651-653.
76 衡先培, 张朝春. 实用糖尿病手册. 成都: 四川科学技术出版社, 2000, 144-145.
77 王佳珍, 黄小明, 陈秀芳. 月见草油和多烯康对糖尿病大鼠胰岛素抵抗的治疗作用. 浙江医学, 1998, 20(1): 24.
78 尹义存, 邹大进, 鲁瑾. 水飞蓟宾对高脂饮食大鼠胰岛素敏感性的影响. 第二军医大学学报, 1999, 20(4): 231-233.
79 张淑玲, 朱闽, 沈迪. 根皮甙治疗糖尿病的实验研究. 中国中西医结合脾胃杂志, 1996, 4(3): 151-153.
80 方朝晖, 陶文, 杨升杰, 等. 真菌降脂素对糖尿病模型大鼠血脂质、胰岛素、C 肽及血液流变性的影响. 中医药研究, 1997, 13(1): 42-44.
81 徐梓辉, 周世文, 黄林清, 等. 薏苡仁多糖对实验性 2 型糖尿病大鼠胰岛素抵抗的影响. 中国糖尿病杂志, 2002, 10(1): 44-48.
82 郭洁文, 潘竞锵, 邱光清, 等. 荔枝核增强 2 型糖尿病-胰岛素抵抗大鼠胰岛素敏感性作用. 中国新药杂志, 2003, 12(7): 526-529.
83 郭洁文, 廖惠芳, 潘竞锵, 等. 荔枝核皂苷对地塞米松致胰岛素抵抗糖尿病大鼠血糖血脂的影响. 广东药学, 2003, 13(5): 32-35.
84 徐卫东, 林君如, 朱姗颖, 等. 复方苦瓜饮对 2 型糖尿病大鼠模型胰岛素抵抗的影响. 江苏大学学报(医学版), 2003, 13(2): 99-100.
85 Vikrant V, Grover JK, Tandon N. Treatment with extracts of momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J Ethnopharmacol, 2001, 76(2): 139-143.
86 王芬, 万金兰, 陈坤, 等. 苦瓜对胰岛素抵抗鼠肾组织中一氧化氮合成酶的影响. 湖北预防医学杂志, 2003, 14(6): 19-22.
87 玉从容, 吕俊华, 王丹. 葛根素抗氧化作用与改善胰岛素抵抗综合征模型大鼠胰岛素敏感性、血压和血脂作用的实验研究. 上海中医药杂志, 2006, 40(4): 53-55.
88 庆方, 潘竞锵, 肖柳英, 等. 葛根素增强胰岛素抵抗-高血压大鼠胰岛素敏感性作用机制研究. 中国现代应用药学杂志, 2006, 23(9): 868-871.
89 赵慧娟, 陶正贤, 龙明智, 等. 姜黄素对代谢综合征大鼠血浆 TNF-α 和血清 sICAM-1水平的影响. 中国康复医学杂志, 2006, 21(7): 599-601.
90 熊曼琪, 林安钟, 朱章志, 等. 加味桃核承气汤对Ⅱ型糖尿病大鼠胰岛素抵抗的影响. 中国中西医结合杂志, 1997, 17(3): 165-168.
91 申竹芳, 谢明智, 刘海帆. 金芪降糖片对实验动物血脂、胰岛素抗性及免疫功能的影响. 中药新药与临床药理, 1997, 8(1): 23.
92 方朝晖, 鲍陶陶, 王开成, 等. 丹蛭降糖胶囊对糖尿病胰岛素抵抗大鼠骨骼肌葡萄糖转运体基因表达的影响. 中国实验方剂学杂志, 2006, 12(6): 32-35.
93 方朝晖, 王佑民, 王开成, 等. 丹蛭降糖胶囊对胰岛素抵抗大鼠 PPAR-γ mRNA 表达的影响. 中国实验方剂学杂志, 2006, 12(4): 36-39.
94 王开成, 方朝晖. 丹蛭降糖胶囊对胰岛素抵抗大鼠抵抗素的影响. 中国中医药信息杂志. 2006, 13(7): 27-29.
95 王开成, 方朝晖. 丹蛭降糖胶囊对胰岛素抵抗大鼠脂联素的影响. 江西中医学院学报, 2006, 18(2): 61-63.
96 陆灏, 叶伟成, 丁学屏. 三黄片对胰岛素抵抗大鼠 TNF-α、FFA 的影响. 浙江中西医结合杂志, 2003, 13(12): 750-751.
97 李怡, 张前进, 李秋贵, 等. 糖肾胶囊对 FFR 胰岛素抵抗性与 leptin 浓度的影响. 中国实验方剂学杂志, 2000, 6(1): 25-27.
98 王凌, 李秋贵, 浦信行, 等. 参地降糖颗粒对高果糖大鼠胰岛素抵抗的影响. 中医杂志, 2001, 42(11): 686-688.
99 赵旭燕, 李玉明, 王波. 糖脂消对胰岛素抵抗性高血压大鼠胰岛素抵抗性和血清瘦素水平的影响. 中国慢性病预防与控制, 2004, 12(1): 6-8.
100 陆付耳, 杨明炜, 邹欣. 补肾通脉方对 2 型糖尿病大鼠胰岛素抵抗的影响. 华中科技大学学报(医学版), 2002, 31(1): 73-75.
101 黄冬梅, 陆付耳, 黄光英. 补肾通脉方对胰岛素抵抗大鼠胰岛素信号转导的影响. 中国中西医结合杂志, 2003, 23(9): 684-687.
102 司晓晨, 潘杨, 尚文斌. 胰敏胶囊治疗果糖诱导大鼠的胰岛素抵抗. 福建中医药, 2003, 34(5): 43-46.
103 程海波, 尚文斌, 司晓晨. 胰敏胶囊阻止高脂膳食诱导大鼠胰岛素抵抗的发生. 南京中医药大学学报, 2003, 19(5): 281-284.
104 王智明, 李道本, 陈璐璐, 等. 调肝泻火汤防治大鼠胰岛素抵抗的实验研究. 中国中西医结合消化杂志, 2002, 10(2): 81-83.
105 叶爱丽, 陆付耳, 徐丽君. 黄连解毒汤对胰岛素抵抗大鼠脂肪组织胰岛素受体及其底物信号转导的影响. 中国中西医结合杂志, 2006, 26(10): 909-912.
106 李莉芬, 王世东, 姜淼, 等. 人参黄连对 2 型糖尿病胰岛素抵抗大鼠糖脂代谢的影响. 中国中医基础医学杂志, 2006, 12(9): 707-708.
107 夏卫军, 金妙文. 三地降糖片对实验性 NIDDM 大鼠的影响. 江苏中医, 2001, 22(5): 41-43.
108 加藤麦. 艾灸对胰岛素抵抗的治疗效果. 全日本针灸学会杂志, 2002, 52(4): 442-445.
109 谌剑飞, 马雅玲, 丁萍, 等. 针刺对 2 型糖尿病患者免疫细胞因子、胰岛素敏感指数及血凝指标的影响. 中医杂志, 2002, 43(1): 30-32.
110 刘志诚, 孙凤岷, 马志民, 等. 针刺对非胰岛素依赖性糖尿病大鼠渴中枢的作用. 中国针灸, 2002, 22(2): 121-124.
111 葛子, 王少宁, 张国玺, 等. 针刺对下丘脑内与糖代谢等有关酶的影响. 中国针灸, 1984, 4(6): 31.
112 许能贵, 梁兴伦. 针刺对自发性高血压大鼠血压及胰岛素抵抗的效应研究. 中国针灸, 1997(8): 493-497.
113 祁燕, 张泳南, 谢自敬. 针刺对 2 型糖尿病大鼠胰岛素抵抗的作用. 中国临床康复, 2006, 10(43): 166-170.
114 易纬, 孙健, 许能贵, 等. 针刺对胰岛素抵抗模型大鼠肝脏和胰腺的形态学影响. 新中医, 2007, 39(1): 104-106.
1 刘振平. 运动和代谢综合征. 中国运动医学杂志, 2000, 19(2): 191.
2 Tsujinaka K, Nakamura T, Imaeda H, et al. A high lipid peroxide diet feeting facilities normal rats to insulin resistance and β-cell apoptosis. Diabetes, 2000, 49(Suppl 1): A420.
3 Meigs JB. Epidemiology of the metabolic syndrome. Am J Manag Care, 2002, 8(Suppl 11): S283-292.
4 Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation, 2003, 108: 420-425.
5 Ford ES, Giles WH. A comparison of the prevalance of the metabolic syndrome using two proposed definitions. Diabetes Care, 2003, 26: 575-581.
6 Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose reverse diabetes in lipoatrophic mice.J Clin Invest, 2000, 105: 271-278.
7 Jia WP, Xiang KS, Chen L, et al. Epidemiologic study on metabolic syndrome in normal and overweight Chinese in Shanghai. Diabetes, 2000, 49(Suppl 1): A148.
8 顾东风, Reynolds K, 杨文杰, 等. 中国成年人代谢综合征的患病率. 中华糖尿病杂志, 2005, 13(3): 181-186.
9 脑卒中、冠心病发病危险因素进一步研究协作组. 中国 11 个省的代谢综合征流行病学调查. 中华预防医学杂志, 2002, 36(5): 298.
10 张红叶, 史秀忠, 孙凯, 等. 代谢综合征患病率及分布特点——青岛港健康研究. 高血压杂志, 2003, 11(1): 77-80.
11 陈蕾, 贾伟平, 陆俊茜, 等. 上海市成人代谢综合征流行病学调查. 中华心血管病杂志, 2003, 31: 909-912.
12 李秀钧, 钱荣立. 美国糖尿病学会第 64 届学术年会代谢综合征专题简介. 中华糖尿病杂志, 2004, 12(5): 377.
13 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998, 15: 5392-5531.
14 WHO. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel) final report. Circulation, 2002, 106: 3121-3143.
15 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议. 中华糖尿病杂志, 2004, 2(3): 156.
16 宋秀霞译. 国际糖尿病联盟代谢综合征全球共识定义. 中华糖尿病杂志, 2005, 13(3): 178-180.
17 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol, 1979, 237(3): E214-223.
18 Bergman RN. Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes, 1989, 38: 1512.
19 Steil GM, Murrary J, Bergman RN, et al. Repeatability of insulin sensitivity and glucose effectiveness from the minimal model: implication for study design. Diabetes, 1994, 43: 1365.
20 Steil GM, Volund A, Kahn SZ, et al. Reduced sampled number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes, 1992, 42: 250.
21 夏红, 李燕等. 减少样本数的最小模式对Ⅱ型糖尿病患者胰岛素抵抗的临床应用研究.中国糖尿病杂志, 1996, 4(1): 3-6.
22 Coates PA, Ollerton RL, Luzio SD, et al. Reduced sampled protocols in estimation of insulin sensitivity and glucose effectiveness using the minimal model in NIDDM. Diabetes, 1993, 42: 1635.
23 Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Clin Pract, 1990, 10: 167.
24 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-1 cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 1985, 28: 412-419.
25 Haffner S, Gonzaler C, Miettinen A, et al. A prospective analysis of the Homa model. the Mexico City Diabetes Study. Diabetes Care, 1996, 19: 1138-1141.
26 李光伟, 潘孝仁, Lillioja S, 等. 监测人群胰岛素敏感性的一项新指数. 中华内科杂志, 1993, 12(10): 656-660.
27 Caro JF, Clinical review 26. Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab. 1991, 73: 691-695.
28 丁荣蓉, 毛季萍. 2 型糖尿病大血管病变机理和糖尿病治疗. 医学与哲学 2004, 25(11): 41-42.
29 Mogul HR, Weinstein BI, Mogul DB, et al. Syndrome W: a new model of hyperinsulinemia, hypertension and midlife weight gain in healthy women with normal glucose tolerance. Heart Dis, 2002, 4(2): 78-85.
30 Wajchenberg BL, Giannella-Neto D, da-Silva ME, et al. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res, 2002, 34(11-12): 616-621.
31 Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med, 2001, 250: 105-120.
32 Mercado MM, McLenithan JC, Silver KD, et al. Genetics of insulin resistance. Curr Diab Rep, 2002, 2: 83-95.
33 Mi J, Law C, Zhang KL, et al. Effects of infant birthweight and maternal body mass index in pregnancy of components of the insulin resistance syndrome in China. Ann Intern Med,2000, 132: 253-260.
34 Vitaliano PP, Scanlan JM, Zhang J, et al. A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosom Med, 2002, 64(3): 418-435.
35 Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence. Metabolism, 2002, 51(12): 1573-1577.
36 田成功, 邵加庆, 于镔. 瘦素: 胰岛素抵抗的独立危险因素. 中华内分泌代谢杂志, 2002, 18(3): 184-187.
37 刘超, 周红文. 瘦素和代谢综合征. 辽宁实用糖尿病杂志, 2002, 10(4): 2-4.
38 Assali AR, Ganor A, Beigel Y, et al. Insulin resistance in obesity: body weight or energy balance? J Endocrinol, 2001, 171(2): 293.
39 李东锋, 杨汉东, 杨波, 等. 代谢综合征患者血清瘦素与血脂、肥胖及胰岛素抵抗关系的研究. 实用医学杂志. 2005, 21(17): 1911-1913.
40 张俊清, 高研, 郭晓惠, 等. 肥胖青少年血清瘦素、胰岛素和胰岛素原水平的变化. 中华内科杂志, 2002, 41(4): 221-223.
41 Kondo H, Shimomura I, Katsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes, 2002, 51(7): 23-25.
42 Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 2001, 50(5): 1126.
43 Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med, 2005, 257: 167-175.
44 Yamauchi T, Oike Y, Kamon J, et al. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Net Genet, 2002, 30(2): 211.
45 Berg AH, Combs TP, Schrere PE, et al. adponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab, 2001, 13(20): 84.
46 张艳芳, 吴汉妮. 抵抗素与胰岛素抵抗. 国外医学分子生物学分册, 2003, 25(5): 297 299.
47 鲁瑾, 邹大进, 张家庆. 肿瘤坏死因子-α 致胰岛素抵抗. 中国病理生理杂志, 1999, 15(12): 1146-1148.
48 顾鸣宇, 盛正妍. 胰岛素抵抗与脂肪肝. 国外医学内分泌分册, 2003, 23(增刊): 32-33.
49 余丹箐, 高鑫, 赵耐青, 等. 肥胖患者血清 C-反应蛋白水平变化与代谢综合征的关系. 复旦学报(医学版), 2002, 29(1): 45-49.
50 韩萍, 何冰, 崔力, 等. C 反应蛋白和白细胞介素 6 以及肿瘤坏死因子 α 对 2 型糖尿病和代谢综合征发生的影响. 中国糖尿病杂志, 2003, 11(1): 57-58.
51 杨郁, 李昌臣. 炎症与代谢综合征. 实用糖尿病杂志, 2005, 1(2): 13-15.
52 孙东升, 张继业. 纤溶酶原激活物抑制剂-1 与代谢综合征. 心血管病学进展, 2001,22(5): 303-304.
53 宁光, 陈家伦. 胰岛素抵抗状态下 HepG2 细胞纤维蛋白溶解酶原激活物抑制物-1 基因表达. 中华内分泌代谢杂志, 2000, 16(4): 239-242.
54 Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes, 2004, 53: 336-346.
55 朱旅云, 刘坤申. 胰岛素抵抗与内皮功能障碍. 国外医学内分泌分册, 2002, 22(5): 319-320 .
56 余叶容, 李宏亮, 喻红玲, 等. 单纯性肥胖患者胰岛素抵抗与内皮依赖性血管舒张动能的研究. 中华医学杂志, 2003, 83(17): 1467-1470.
57 刘金来, 郝宝顺, 朱承明, 等. 代谢综合征患者危险因素聚集对血管内皮功能的影响. 中国临床康复, 2005, 9(3): 63-65.
58 朱族云, 刘坤申. 胰岛素抵抗与内皮细胞障碍. 国外医学内分泌学分册, 2002, 22(9): 319-320.
59 漆泓, 孙明, 周宏研. MS 患者空腹血清游离脂肪酸水平与胰岛素抵抗的关系. 临床内科杂志, 2003, 20(7): 353-355.
60 Vetter R, Lombardi AM, Fabris R, et al. Substrate competition and insulin action in animal models. Int J Obes Relat metab Disord, 2000, 24[Suppl 2]: S22-24.
61 Whorwood CB, Donovan SJ, Flanagan D, et al. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes, 2002, 51 (4): 1066-1075.
62 Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science, 2001, 294(5549): 2166-2170.
63 Terzolo M, Pia A, Ali A, et al. Adrenal incident aloma: a new cause of themetabolic syndrome. J Clin End Ocrinol Metab, 2002, 87(3): 998-1003.
64 Hjemdahl P. Stress and the metabolic syndrome: an interesting but enigmatic association. Circulation, 2002, 106: 2634-2636.
65 纪立农. 代谢综合征与 2 型糖尿病. 国外医学内分泌学分册, 2002, 22(5): 281-282.
66 Eckle RH, Grundy SM, Zimmet PZ. The metabolism syndrome. Lancet, 2005, 365: 1415-1428.
67 Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol, 1999, 84: 11-14.
68 Despres JP, Beno it L, Pascale M, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med, 1996, 334: 952-957.
69 Jia WP, Lu JX, Xiang KS, et al. Prediction of abdominal visceral obesity from body mass index, waist circumference and waist-hip ratio in Chinese adults: receiver operating characteristic curves analysis. Biomed Environ Sci, 2003, 16: 206-211.
70 洪洁, 顾卫琼, 张翼飞, 等. 糖耐量不同的代谢综合征患者胰岛素抵抗和胰岛 β 细胞1 相胰岛素分泌功能的研究. 中华医学杂志, 2003, 83(22): 1952-1956.
71 Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension, 1992, 19: 403-409.
72 Haffner SM, Ferrannini E, Hazuda HP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension, 1992, 20: 38-43.
73 Isomaa B, Aimgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24: 683-689.
74 窦相峰, 张红叶, 孙凯, 等. 中国汉族人代谢综合征与脑卒中密切相关. 中华医学杂志, 2004, 84: 539-542.
75 徐焱成. 胰岛素抵抗综合征的研究近况. 医学新知杂志, 2004, 14(2): 78-81.
76 范建高. 非酒精性脂肪肝与代谢综合征. 国外医学内分泌学分册, 2002, 22 (5): 284.
77 Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med, 1999, 107: 450-455.
78 Sanyal AJ, Campbell-sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120: 1183-1192.
79 罗瑞华, 李晔, 黄学文. 非酒精性脂肪肝与代谢综合征的关系探讨. 中国临床医学, 2004, 11(5): 742-744.
80 Eugene C. The relationship between systemic hypertension and obstructive sleep apnea facts and theory. Am J Med, 1995, 98(10): 118.
81 肖丹, 康健, 王秋月, 等. 阻塞性睡眠呼吸暂停患者睡眠时高血压的发生. 中华结核和呼吸杂志, 1998, 21(11): 654.
82 慈书平, 江时森. 睡眠呼吸暂停与多系统器官损害研究进展. 中华结核和呼吸杂志, 1997, 20(1): 39.
83 慈书平, 范玮, 刘树森, 等. 老年人睡眠呼吸暂停综合征与糖代谢紊乱. 中国老年学杂志, 1995, 15(4): 20.
84 Parish JM, Shepar JW. Cardiovascular effects of sleep disorders. Chest, 1990, 97(5): 1220.
85 路影, 蓝红林, 马维红. 老年 2 型糖尿病患者微量白蛋白尿与胰岛素抵抗的关系. 中华老年医学杂志, 1999, 18(2): 77-79.
86 路影, 尹友生, 蓝红林, 等. 血压正常的 2 型糖尿病患者微量白蛋白尿与胰岛素抵抗的关系. 中华肾脏病杂志, 1999, 15(2): 116-117.
87 Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al. Microalbum inuria is associated with insulin resistance in nodiabetic subjects: the insulin resistance athero sclerosis study. Diabetes, 1998, 47(5): 793-800.
88 Catalano C, Muscelli E, Quinones GA, et al. Effect of insulin on systemic and renal handing of album in nondiabetic and NIDDM subjects. Diabetes, 1997, 46(5): 868-875.
89 Spangler JG, Konen JC. Hypertension, hyperlipodemia, and abdominal obesity and the development of microalbuminuria in patients with non-insulin-dependent diabetes mellitus. J Am Board Fam Pract, 1996, 9: 1-6.
90 Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens. 1999, 17(7): 869-872.
91 Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults. Ann Epidemiol, 1998, 8(4): 250-261.
92 杜鹃. 有氧运动改善胰岛素抵抗综合征的研究进展. 国外医学内分泌学分册, 2004, 24(5): 347-349.
93 Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol, 2004, 93: 136-141.
94 Pyorala K, Ballantyne C, Lee M, et al. Reduction of coronary events by simvastatin in non–diabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analysis of the Scandinavian Simvastat in Survival Study. Diabetes, 2003, 52: A19.
95 Rubins H B, Robins S J, Collins D, et al. Diabetes, plasmainsulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VAHIT). Arch Int Med, 2002, 162: 2597-2604.
96 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342(3): 145-153.
97 American Diabetes Association. Implication of the United Kingdom Prospective Diabetes Study. Diabetes care, 1998, 21: 2180-2185.
98 Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome, systematic review and meta-analysis. BMJ, 2003, 327: 951-956.
99 郭冀珍, 龚艳春, 章建梁, 等. 高血压病伴代谢综合征患者 463 例的干预治疗研究. 中华心血管病杂志. 2005, 33(2): 132-136.
100 王志国, 杨晔, 高连如, 等. 行为干预加二甲双胍对代谢综合征生物学和血生化指标的影响. 中国临床康复, 2004, 8(18): 3528-3529.
101 Stephen Smith. 罗格列酮改善胰岛素抵抗和 β 细胞功能及对心血管的潜在保护作用. 国外医学内分泌学分册, 2002, 22(5): 284-286.
102 Grundy SM, Brewer B, Cleeman JI, et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conferenceon Scientific Issue Related to Definition. Circulation, 2004, 109: 433-438.
1 宋秀霞译. 国际糖尿病联盟代谢综合征全球共识定义. 中华糖尿病杂志, 2005, 13(3): 178-180.
2 吕仁和, 张法荣, 高彦彬, 等. 消渴病(糖尿病)的分期辨证与疗效评价标准. 中国医药学报, 1993, 8(3): 50-56.
3 郑筱萸. 中药新药临床研究指导原则(试行). 北京: 中国医药科技出版社, 2002, 85-89, 233-237, 383-384.
4 李光伟, 潘孝仁, Lillioja S, 等. 监测人群胰岛素敏感性的一项新指数. 中华内科杂志, 1993, 12(10): 656-660.
5 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-1 cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 1985, 28: 412-419.
6 Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial ysfunction in children and adults at risk of atherosclerosis. Lancet, 1992, 340: 1111-1117.
7 褚熙, 吕学成, 王艳清, 等. 代谢综合征患者肱动脉血管顺应性的超声研究. 中国中西医结合影像学杂志, 2005, 3(3): 178-180.
8 顾东风, Reynolds K, 杨文杰, 等. 中国成年人代谢综合征的患病率. 中华糖尿病杂志, 2005, 13(3): 181-186.
9 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议. 中华糖尿病杂志, 2004, 12(3): 156-161.
10 《中国糖尿病防治指南》编写组. 中国糖尿病防治指南. 北京: 北京大学医学出版社, 2004 年 1 月第一版, 46-47.
11 徐晖. 泽泻药理作用研究进展. 湖南中医杂志, 2004, 20(3): 77-78.
12 张林丽. 茵陈的药理研究和临床应用近况. 广酉医学, 2003, 25(11): 2185-2186.
13 闫瑾. 丹参及其有效成分的药理作用研究述略. 中医药学刊, 200, 22(9): 1725-1726.
14 邢淑丽, 黄文政, 郑君英. 中药鬼箭羽的临床和实验研究进展. 吉林中医药, 2005, 25(11): 62-63.
15 余园媛, 王伯初, 彭亮, 等. 黄连的药理研究进展. 重庆大学学报(自然科学版), 2006, 29(2): 107-111.
16 刘凯, 郑海生. 大黄酸的药理作用研究述略. 中医药学刊, 2004, 22(9): 1732-1734.
17 刘俊芳, 朱建华. 内皮功能障碍、炎症与动脉粥样硬化. 浙江医学, 2005, 27(11): 875-879.
18 夏菲. 胰岛素抵抗与凝血纤溶系统功能异常. 国外医学生理病理科学与临床分册, 2005, 25(3): 221-222
19 杨义生, 洪洁, 顾卫琼, 等. 脂肪组织的分泌功能与代谢综合征. 国外医学内分泌学分册. 2004, 24(3): 156-159.
20 张运, 张 梅, 陈文强, 等. 易损斑块的认识与研究进展. 心脏病学实践 2004-规范化治疗.北京: 人民卫生出版社, 2004: 233-245.
21 Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med, 1994, 331: 417- 424.
22 李英兰, 滕长青. 同型半胱氨酸与缺血性心脑血管病关系的研究进展. 中国老年学杂志, 2003, 9(23): 26.
23 Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res, 2001, 89: 763- 771.
24 王宏宇, 胡大一. 血管内皮功能检测的临床应用. 中国医刊, 2003, 38(3): 57-59.
1 曹廷兵, 闫振成, 沈成义, 等. 代谢综合征大鼠模型的建立及其相关基因表达变化的研究. 解放军医学杂志, 2005, 30(8): 702-705.
2 程海波, 司晓晨, 尚文斌, 等. 高脂饲料和高果糖餐分别诱导胰岛素抵抗大鼠模型的胰岛素敏感性. 中医临床康复, 2006, 10(7): 121-123.
3 Storlien LH, Pan DA, Kusunoki Metal. Effects of benfluorex on in vivo patterns of insulin resistance induced by diet rich in fat or fructose. Diabetes/ Metabolism Rev, 1993, 9(suppl 1): 65S-72S.
4 Fueger PT, Bracy DP, Malabanan CM, et al. Hexokinase Ⅱ over expression improves exercise-stimulated but not insulin-stimulated muscle glucose uptake in high-fat-fed C57BL/6J mice. Diabetes, 2004, 53: 306-314.
5 Youngren JF, Paik J, Barnard RJ. Impaired insulin-receptor autophosphorylation is a nearly defect in fat-fed, insulin-resistant rats. J Appl Physiol, 2001, 91: 2240-2247.
6 Mithieux G, Guignot L, Bordet JC, et al. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high–fat diet. Diabetes, 2002, 51: 139-143.
7 Chan CB, Deleo D, Joseph JW, et al. Increased uncoupling protein-2 levels in β-cells are associated with impaired glucose-stimulated insulin secretion. Diabetes, 2001, 50: 1302-1310.
8 Tremblay F, Lavigne C, Jacques H, et al. Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinase C(ξ/λ) activities. Diabetes, 2001, 50: 1901-1910.
9 Kim C H, Youn J H, Park J Y, et al. Effects of high-fat diet and exercise training on intracellular glucose metabolism in rats. Am J Physiol Endocrinol Metab, 2000, 278: E977-E984.
10 Perriello G, Misericordia P, Volpi E, et al. Contribution of obesity to insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1995, 80: 2464-2469.
1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285: 2486-2497.
2 Ross R. Cell biology of atherosclerosis. Ann Rev Physiol, 1995, 57: 791-795.
3 Feata A, D’Agostino RJr,Howard G, et al. Chronic subclinicial inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study(IRAS). Circulation, 2000, 102: 42-47.
4 Yudhin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in health subjects: association with obesity, insulin resistance, and endothelial dysfunction: a potential role of cytokines origination from adipose tissue? Atheroscler Thromb Vase Biol, 1999, 19: 972-978.
5 秦海春, 郭强, 王芸. 肝硬化患者 TNF-α, IL-6, HA, CIV 水平测定的临床意义. 中国现代医学杂志, 2002, 12(1): 36-37.
6 信涛, 徐玉清, 姜秋颖, 等. TNF-α 和 Bcl-2 在大肠癌中的表达及意义. 中国现代医学杂志, 2003, 13(13): 87-89.
7 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: director role in obesity-linked insulin resistance. Science, 1993, 259: 87-91.
8 Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-α: in human obesity and insulin resistance. J Clin Invest, 1995, 95(5): 2409-2415.
9 Fried SK, Zechner R. Cachection/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis and activity. J Lipid Res, 1989, 30: 1917-1923.
10 Kern PA, Saghizadeh M, Ong JM, et al. The expression of TNF-α in human adipose tissue regulation by obesity, weight loss and relationship to lipoprotein lipase. J Clin Invest, 1995, 95: 2111-2119.
11 Prins JB, Niesler CV, Winterford CM, et al. Tumor necrosis factor-α induced apotosis of human adipose cell. Diabetes, 1997, 46: 1939-1944.
1 Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol, 2002, 13: 51-59.
2 Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules. Circulation, 1999, 100(25): 2473-2476.
3 Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol, 2003, 23: 85-89.
4 Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res, 2000, 32: 47-50.
5 Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem, 2002, 277(40): 37487- 37491.
6 Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE deficient mice from atherosclerosis. J Biol Chem, 2003, 278(4): 2461-2468.
7 Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E deficient mice. Circulation, 2002, 106: 2767-2670.
8 Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 2002, 105(24): 2893-2898.
9 Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun, 1999, 257: 79-83.
10 Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001, 86: 1930-1935.
11 梁晓萍, 韩全水, 文锦丽, 等. 超重和肥胖人群高血压病的患病率及血清脂联素水平的变化. 中华心血管病杂志, 2006, 34(1): 41-44.
12 陆俊茜, 贾伟平, 王遂军, 等. 血清脂联素水平降低是代谢综合征的特征性标志. 上海医学, 2005, 28(8): 650-652.
13 Yang WS, Lee WJ, Funahashi T, et al. Weight induction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clini Endocrinol Metab, 2001, 86: 3815-3819.
14 Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol, 2000, 20: 1595-1599.
15 Lihn AS, Ostergard T, Nyholm B, et al. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab, 2003, 284: 443-448.
16 Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 2001, 50 (5): 1126-1133.
2 赵天豫, 段军, 仝小林. 中医治疗糖尿病的新思路. 光明中医, 2002, 17(5): 12-13.
3 李东晓. 痰与代谢综合征. 中国中医基础医学杂志, 2005, 11(2): 144-145.
4 柴可夫, 王亚丽. 从痰瘀论治胰岛素抵抗. 中华中医药杂志, 2005, 20(9): 542-543.
5 袁肇凯, 黄献平, 简亚平, 等. 高脂血症痰瘀证候与胰岛素抵抗的关系. 中国医药学报, 2003, 18(8): 468-470.
6 徐远. 中医治疗代谢综合征的思路与方法. 中医杂志, 2003, 44(4): 301-302.
7 刘承琴, 赵建群. 2 型糖尿病胰岛素抵抗重视从脾论治的思路. 新中医, 2003, 35(9): 28-29.
8 李锡杰, 刘志龙. 论从脾论治代谢综合征. 中医药导报, 2006, 12(4): 9-11.
9 王智明. 胰岛素抵抗从肝论治的探讨. 光明中医, 2003, (18)6: 13-14.
10 王德玉, 徐志瑛. 论肝与代谢综合征. 浙江中西医结合杂志, 2004, 14(1): 23-24.
11 董卫. 综合治疗胰岛素抵抗综合征 56 例. 山西中医, 2004, 20(6): 17.
12 杨文军, 庄严. 胰岛素抵抗综合征辨治初探. 山东中医药大学学报, 2002, 26(4): 275-276.
13 张德贵, 贺建丽. 调肝滋肾法治疗胰岛素抵抗及其相关性疾病之临证与探讨. 光明中医, 2002, 17(4): 26-27.
14 吴深涛. 对胰岛素抵抗宜用益肾化瘀、疏利少阳法. 中医杂志, 2001, 42(6): 332-333.
15 张玉金, 张文艺. 高血压病辨证分型和胰岛素抵抗关系的探讨. 河南中医, 2001, 21(1): 36.
16 梁兴伦, 韩明向. 胰岛素抵抗模型大鼠的中医证候研究. 中国中西医结合杂志, 2001, 21(7): 528-530.
17 朱章志, 熊曼琪. Ⅱ型糖尿病患者不同证型红细胞胰岛素受体缺陷的观察. 中国中西医结合杂志, 1995, 15(5): 266-268.
18 周国英, 武雪萍, 衡先培, 等. Ⅱ型糖尿病气阴两虚证与胰岛素抵抗的相关性研究. 福建中医药, 2000, 31(2): 7-8.
19 于顾然, 贺燕勤, 郭云庚, 等. 冠心病中医证型与胰岛素抵抗、脂质及红细胞膜 ATP酶关系的临床研究. 中医杂志, 2000, 41(2): 111-112.
20 常宗范, 冯奕超. 胰岛素抵抗的中医辨证论治. 吉林中医药, 2001, (3): 54-55.
21 陈思兰, 林兰, 楚晓燕. Ⅱ型糖尿病中医辨证分型与胰岛素抵抗的相关性分析. 中国中医药信息杂志, 2001, 8(6): 49-51.
22 刘惠文, 张铁志, 李光伟, 等. 高血压病患者胰岛素抵抗与中医辨证分型的相关性研究. 中国中西医结合杂志, 1999, 19(4): 200.
23 李秋炎, 贾太平, 赵展荣, 等. Ⅱ型糖尿病患者中医辨证分型与胰岛 β 细胞功能关系的研究. 中医杂志, 1998, 39(7): 428.
24 黎学松, 岑永庄, 梁干雄, 等. Ⅱ型糖尿病中医分型与胰岛素抵抗相关性分析. 辽宁中医杂志, 1998, 25(8): 345.
25 王喜瑛, 郑姜卿, 吕绍光. 36 例 2 型糖尿病中医不同证型的胰岛素抵抗观察. 福建中医学院学报, 2003, 13(6): 8-9.
26 王琦, 李英帅. 中医对代谢综合征的认识及辨治探讨(下). 浙江中医杂志, 2006, 41(11): 623-625.
27 倪艳霞, 刘安强, 高云峰, 等. 黄连素治疗Ⅱ型糖尿病 60 例疗效观察及实验研究. 中西医结合杂志, 1988, 8(12): 711-712.
28 陈其明, 谢明智. 黄连及小檗碱降血糖的研究. 药学学报, 1986, 21(6): 401.
29 赵荣华. 518 个糖尿病处方统计分析. 云南中医学院学报, 20(2): 20-23.
30 李志荣. 黄芪多糖冲剂治疗Ⅱ型糖尿病的临床研究. 山西医药, 1995, 11(11): 16.
31 黄立武, 钱海凌, 孙淑荣, 等. 黄芪注射液对老年脑梗死恢复期胰岛素抵抗的影响. 中国康复理论与实践, 2004, 10(1): 55-56.
32 黄春玲, 吕玉萍. 黄芪辅助治疗 2 型糖尿病对胰岛素抵抗的影响. 中国中西医结合杂志, 2003, 23(10): 779-780.
33 黄琦, 许家鸾. 麦冬多糖对 2 型糖尿病血糖及胰岛素抵抗的影响. 浙江中西医结合杂志, 2002, 12(2): 81-82.
34 于志清. 纯单黄酮甙碘-胰岛素与脂肪细胞结合的影响. 广西医学院学报, 1980(1): 22.
35 潘玲, 冯全生. 八味丸方药对代谢综合征患者治疗效应的临床观察. 四川生理科学杂志 2005, 27(2): 87-91.
36 管弦, 黄菲, 吴纪祖, 等. 六味地黄丸银杏叶片对早期 2 型糖尿病胰岛素抵抗与脂毒性的影响. 辽宁中医杂志, 2006, 33(11): 1423-1426.
37 李莉芬, 吴玉红. 金芪降糖片治疗 2 型糖尿病胰岛素抵抗患者的观察. 天津医药, 2006, 34(9): 654-656.
38 陈苹, 朱章志, 郎江明, 等. 益气养阴活血通腑法治疗 2 型糖尿病磺脲类药继发性失效的临床观察. 中国中西医结合杂志, 2004, 11(7): 585-588.
39 陈维铭, 王馨然. 半夏白术天麻汤对单纯性肥胖患者胰岛素抵抗的影响. 现代中西医结合杂志, 2004, 13(2): 351-353.
40 喻红, 邹先智. 地黄饮子对改善糖尿病胰岛素抵抗的疗效观察. 湖南中医药导报, 2001, 7(1): 19.
41 仝小林, 柳红芳, 朴信映, 等. 开郁清胃颗粒治疗Ⅱ型糖尿病胰岛素抵抗的临床研究. 实用中医内科杂志, 2001, 15(2): 10-11.
42 袁肇凯, 黄献平, 田松, 等. 养心通脉片对胰岛素抵抗综合征血脂及甲襞微循环的影响. 湖南中医学院学报, 2003, 23(4): 35-38.
43 黄献平, 袁肇凯, 卢芳国, 等. 养心通脉片对胰岛素抵抗综合征病人红细胞胰岛素受体的影响. 中西医结合心脑血管病杂志, 2003, 1(7): 373-375.
44 黄献平, 袁肇凯, 卢芳国, 等. 养心通脉片对胰岛素抵抗综合征患者红细胞膜的影响. 中国中医药信息杂志. 2003, 10(12): 12-14.
45 卢芳国, 袁肇凯, 黄献平, 等. 养心通脉片对胰岛素抵抗综合征外周血单核细胞C-myc 和 PDGF-A mRNA 表达的影响. 中西医结合心脑血管病杂志. 2003, 1(8): 442-444.
46 刘英华, 陈春梅, 赖育红, 等. 通心络改善糖尿病冠心病患者胰岛素抵抗的观察研究. 天津中医药, 2006, 23(4): 282-283.
47 钱秋海, 庄乾竹. 愈胰饮治疗胰岛素抵抗综合征的临床研究. 中国中医药信息杂志, 2002, 9(7): 12-14.
48 郭志华, 袁肇凯, 王东生. 四泰片治疗高血压病胰岛素抵抗的临床研究. 中成药, 2004, 26(2): 162-164.
49 安其, 李朝敏, 程斌. 安一胶囊治疗胰岛素抵抗综合征的临床观察. 成都中医药大学学报, 2003, 25(1): 10-12.
50 刘宪俊, 杨叔禹, 陈弼沧, 等. 平糖胶囊对气阴两虚型 2 型糖尿病患者胰岛素抵抗干预的研究. 福建中医药, 2006, 37(4): 3-5.
51 宋镇星 . 调谢胶囊治疗代谢综合征疗效观察 . 辽宁中医杂志, 2006, 33(10): 1294-1295.
52 戴飞跃, 黄保民, 唐晨光, 等. 福寿降糖饮治疗 2 型糖尿病胰岛素抵抗的临床观察. 中医药学刊. 2006, 24(8): 1497-1498.
53 徐云生, 杜丙会. 中西医结合治疗 X 综合征 30 例. 山东中医杂志, 1998, 17(5): 224.
54 姜淼. 三黄安消胶囊治疗 2 型糖尿病及改善胰岛素抵抗作用的临床研究. 新中医, 2006, 38(1): 28-30.
55 杨文军, 郭宝荣, 赵泉霖. 中药配合口服降糖药对 2 型糖尿病患者胰岛素抵抗及微量白蛋白尿的影响. 山东中医药大学学报, 2003, 27(4): 285-286.
56 邓德强. 培土活血解毒法治疗 2 型糖尿病及胰岛素抵抗的临床研究. 新中医, 2003, 35(4): 35-37.
57 卢晓琳. 益气养阴活血通腑法治疗胰岛素抵抗综合征 52 例. 河北中医, 2003, 25(4): 270-271.
58 张慧, 郭宏敏. 中药养阴和瘀方对老年代谢综合征胰岛素抵抗及高凝血症的干预作用的研究. 中国老年保健医学杂志, 2006, 4(3): 50-52.
59 刘振杰. 扶脾抑胃法治疗胰岛素抵抗性糖尿病. 湖北中医杂志, 2006, 28(10): 13-14.
60 薛青, 张桦, 李中和, 等. 益肾疏肝泄毒祛瘀法改善 2 型糖尿病早期肾病胰岛素抵抗的研究. 中药材, 2006, 29(10): 1120-1122.
61 刘志诚, 孙凤岷, 朱苗花, 等. 针灸对非胰岛素依赖性糖尿病胰岛素抵抗的影响. 上海针灸杂志, 2000, 19(1): 5-7.
62 谌剑飞, 马雅玲, 蔡绍华, 等. 针刺对糖尿病的抗凝与逆转胰岛素抵抗作用. 上海针灸杂志, 2001, 20(4): 5-7.
63 唐胜修. 头穴对中风后遗症患者胰岛素抵抗的调整作用研究. 安徽中医临床杂志,2002, 14(3): 164-165.
64 魏群利, 刘志诚. 针刺配合耳穴压籽治疗 2 型糖尿病(肥胖型)67 例. 安徽中医学院学报, 2002, 21(3): 34-37.
65 秦福兰, 贾杰, 郭学军. 针刺和运动疗法对 2 型糖尿病的疗效观察. 中国针灸, 2002, 22(9): 579-581.
66 张智龙, 薛莉, 吉学群, 等. 针刺对 2 型糖尿病胰岛素抵抗影响的临床研究. 中国针灸, 2002, 22(11): 723-725.
67 胡葵, 李嘉, 刘志诚. 针灸治疗肥胖型 2 型糖尿病的临床研究. 上海针灸杂志, 2001, 20(4): 8-10.
68 高从容, 张家庆, 黄庆玲. 黄连素增加胰岛素抵抗大鼠模型胰岛素敏感性的研究. 中国中西医结合杂志, 1997, 17(8): 162.
69 陆灏, 叶伟成, 丁学屏. 黄连素对实验大鼠胰岛素抵抗的影响. 辽宁中医学院学报, 2002, 4(4): 259-260.
70 谢宗长, 钱振坤, 柳重威. 人参抗实验性糖尿病大鼠脂质过氧化损伤的研究. 中国中西医结合杂志, 1993, 13(5): 289-290.
71 胡翠华, 徐华丽, 于晓风, 等. 人参二醇组皂苷对实验性 2 型糖尿病大鼠血糖及血脂代谢的影响. 吉林大学学报(医学版), 2006, 32(6): 1004-1008.
72 刘永玉, 毛良, 莫启忠, 等. 实验性 2 型糖尿病大鼠的胰岛素抵抗性. 中国病理生理杂志, 1991, 7(4): 422-425.
73 祁忠华, 林善镁, 黄宇峰, 等. 黄芪改善糖尿病肾病早期血流动力学异常的研究. 中国糖尿病杂志, 1999, 7(3): 147-149.
74 鲁瑾, 邹大进, 张家庆. 黄芪预防肿瘤坏死因子-α 所致胰岛素抵抗. 中国中西医结合杂志, 1999, 19(7): 420-422.
75 金椿, 戴瑞鸿, 周峰, 等. 黄芪对冠心病患者红细胞内钠含量和钠转运的影响. 中西医结合杂志, 1991(11): 651-653.
76 衡先培, 张朝春. 实用糖尿病手册. 成都: 四川科学技术出版社, 2000, 144-145.
77 王佳珍, 黄小明, 陈秀芳. 月见草油和多烯康对糖尿病大鼠胰岛素抵抗的治疗作用. 浙江医学, 1998, 20(1): 24.
78 尹义存, 邹大进, 鲁瑾. 水飞蓟宾对高脂饮食大鼠胰岛素敏感性的影响. 第二军医大学学报, 1999, 20(4): 231-233.
79 张淑玲, 朱闽, 沈迪. 根皮甙治疗糖尿病的实验研究. 中国中西医结合脾胃杂志, 1996, 4(3): 151-153.
80 方朝晖, 陶文, 杨升杰, 等. 真菌降脂素对糖尿病模型大鼠血脂质、胰岛素、C 肽及血液流变性的影响. 中医药研究, 1997, 13(1): 42-44.
81 徐梓辉, 周世文, 黄林清, 等. 薏苡仁多糖对实验性 2 型糖尿病大鼠胰岛素抵抗的影响. 中国糖尿病杂志, 2002, 10(1): 44-48.
82 郭洁文, 潘竞锵, 邱光清, 等. 荔枝核增强 2 型糖尿病-胰岛素抵抗大鼠胰岛素敏感性作用. 中国新药杂志, 2003, 12(7): 526-529.
83 郭洁文, 廖惠芳, 潘竞锵, 等. 荔枝核皂苷对地塞米松致胰岛素抵抗糖尿病大鼠血糖血脂的影响. 广东药学, 2003, 13(5): 32-35.
84 徐卫东, 林君如, 朱姗颖, 等. 复方苦瓜饮对 2 型糖尿病大鼠模型胰岛素抵抗的影响. 江苏大学学报(医学版), 2003, 13(2): 99-100.
85 Vikrant V, Grover JK, Tandon N. Treatment with extracts of momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J Ethnopharmacol, 2001, 76(2): 139-143.
86 王芬, 万金兰, 陈坤, 等. 苦瓜对胰岛素抵抗鼠肾组织中一氧化氮合成酶的影响. 湖北预防医学杂志, 2003, 14(6): 19-22.
87 玉从容, 吕俊华, 王丹. 葛根素抗氧化作用与改善胰岛素抵抗综合征模型大鼠胰岛素敏感性、血压和血脂作用的实验研究. 上海中医药杂志, 2006, 40(4): 53-55.
88 庆方, 潘竞锵, 肖柳英, 等. 葛根素增强胰岛素抵抗-高血压大鼠胰岛素敏感性作用机制研究. 中国现代应用药学杂志, 2006, 23(9): 868-871.
89 赵慧娟, 陶正贤, 龙明智, 等. 姜黄素对代谢综合征大鼠血浆 TNF-α 和血清 sICAM-1水平的影响. 中国康复医学杂志, 2006, 21(7): 599-601.
90 熊曼琪, 林安钟, 朱章志, 等. 加味桃核承气汤对Ⅱ型糖尿病大鼠胰岛素抵抗的影响. 中国中西医结合杂志, 1997, 17(3): 165-168.
91 申竹芳, 谢明智, 刘海帆. 金芪降糖片对实验动物血脂、胰岛素抗性及免疫功能的影响. 中药新药与临床药理, 1997, 8(1): 23.
92 方朝晖, 鲍陶陶, 王开成, 等. 丹蛭降糖胶囊对糖尿病胰岛素抵抗大鼠骨骼肌葡萄糖转运体基因表达的影响. 中国实验方剂学杂志, 2006, 12(6): 32-35.
93 方朝晖, 王佑民, 王开成, 等. 丹蛭降糖胶囊对胰岛素抵抗大鼠 PPAR-γ mRNA 表达的影响. 中国实验方剂学杂志, 2006, 12(4): 36-39.
94 王开成, 方朝晖. 丹蛭降糖胶囊对胰岛素抵抗大鼠抵抗素的影响. 中国中医药信息杂志. 2006, 13(7): 27-29.
95 王开成, 方朝晖. 丹蛭降糖胶囊对胰岛素抵抗大鼠脂联素的影响. 江西中医学院学报, 2006, 18(2): 61-63.
96 陆灏, 叶伟成, 丁学屏. 三黄片对胰岛素抵抗大鼠 TNF-α、FFA 的影响. 浙江中西医结合杂志, 2003, 13(12): 750-751.
97 李怡, 张前进, 李秋贵, 等. 糖肾胶囊对 FFR 胰岛素抵抗性与 leptin 浓度的影响. 中国实验方剂学杂志, 2000, 6(1): 25-27.
98 王凌, 李秋贵, 浦信行, 等. 参地降糖颗粒对高果糖大鼠胰岛素抵抗的影响. 中医杂志, 2001, 42(11): 686-688.
99 赵旭燕, 李玉明, 王波. 糖脂消对胰岛素抵抗性高血压大鼠胰岛素抵抗性和血清瘦素水平的影响. 中国慢性病预防与控制, 2004, 12(1): 6-8.
100 陆付耳, 杨明炜, 邹欣. 补肾通脉方对 2 型糖尿病大鼠胰岛素抵抗的影响. 华中科技大学学报(医学版), 2002, 31(1): 73-75.
101 黄冬梅, 陆付耳, 黄光英. 补肾通脉方对胰岛素抵抗大鼠胰岛素信号转导的影响. 中国中西医结合杂志, 2003, 23(9): 684-687.
102 司晓晨, 潘杨, 尚文斌. 胰敏胶囊治疗果糖诱导大鼠的胰岛素抵抗. 福建中医药, 2003, 34(5): 43-46.
103 程海波, 尚文斌, 司晓晨. 胰敏胶囊阻止高脂膳食诱导大鼠胰岛素抵抗的发生. 南京中医药大学学报, 2003, 19(5): 281-284.
104 王智明, 李道本, 陈璐璐, 等. 调肝泻火汤防治大鼠胰岛素抵抗的实验研究. 中国中西医结合消化杂志, 2002, 10(2): 81-83.
105 叶爱丽, 陆付耳, 徐丽君. 黄连解毒汤对胰岛素抵抗大鼠脂肪组织胰岛素受体及其底物信号转导的影响. 中国中西医结合杂志, 2006, 26(10): 909-912.
106 李莉芬, 王世东, 姜淼, 等. 人参黄连对 2 型糖尿病胰岛素抵抗大鼠糖脂代谢的影响. 中国中医基础医学杂志, 2006, 12(9): 707-708.
107 夏卫军, 金妙文. 三地降糖片对实验性 NIDDM 大鼠的影响. 江苏中医, 2001, 22(5): 41-43.
108 加藤麦. 艾灸对胰岛素抵抗的治疗效果. 全日本针灸学会杂志, 2002, 52(4): 442-445.
109 谌剑飞, 马雅玲, 丁萍, 等. 针刺对 2 型糖尿病患者免疫细胞因子、胰岛素敏感指数及血凝指标的影响. 中医杂志, 2002, 43(1): 30-32.
110 刘志诚, 孙凤岷, 马志民, 等. 针刺对非胰岛素依赖性糖尿病大鼠渴中枢的作用. 中国针灸, 2002, 22(2): 121-124.
111 葛子, 王少宁, 张国玺, 等. 针刺对下丘脑内与糖代谢等有关酶的影响. 中国针灸, 1984, 4(6): 31.
112 许能贵, 梁兴伦. 针刺对自发性高血压大鼠血压及胰岛素抵抗的效应研究. 中国针灸, 1997(8): 493-497.
113 祁燕, 张泳南, 谢自敬. 针刺对 2 型糖尿病大鼠胰岛素抵抗的作用. 中国临床康复, 2006, 10(43): 166-170.
114 易纬, 孙健, 许能贵, 等. 针刺对胰岛素抵抗模型大鼠肝脏和胰腺的形态学影响. 新中医, 2007, 39(1): 104-106.
1 刘振平. 运动和代谢综合征. 中国运动医学杂志, 2000, 19(2): 191.
2 Tsujinaka K, Nakamura T, Imaeda H, et al. A high lipid peroxide diet feeting facilities normal rats to insulin resistance and β-cell apoptosis. Diabetes, 2000, 49(Suppl 1): A420.
3 Meigs JB. Epidemiology of the metabolic syndrome. Am J Manag Care, 2002, 8(Suppl 11): S283-292.
4 Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation, 2003, 108: 420-425.
5 Ford ES, Giles WH. A comparison of the prevalance of the metabolic syndrome using two proposed definitions. Diabetes Care, 2003, 26: 575-581.
6 Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose reverse diabetes in lipoatrophic mice.J Clin Invest, 2000, 105: 271-278.
7 Jia WP, Xiang KS, Chen L, et al. Epidemiologic study on metabolic syndrome in normal and overweight Chinese in Shanghai. Diabetes, 2000, 49(Suppl 1): A148.
8 顾东风, Reynolds K, 杨文杰, 等. 中国成年人代谢综合征的患病率. 中华糖尿病杂志, 2005, 13(3): 181-186.
9 脑卒中、冠心病发病危险因素进一步研究协作组. 中国 11 个省的代谢综合征流行病学调查. 中华预防医学杂志, 2002, 36(5): 298.
10 张红叶, 史秀忠, 孙凯, 等. 代谢综合征患病率及分布特点——青岛港健康研究. 高血压杂志, 2003, 11(1): 77-80.
11 陈蕾, 贾伟平, 陆俊茜, 等. 上海市成人代谢综合征流行病学调查. 中华心血管病杂志, 2003, 31: 909-912.
12 李秀钧, 钱荣立. 美国糖尿病学会第 64 届学术年会代谢综合征专题简介. 中华糖尿病杂志, 2004, 12(5): 377.
13 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998, 15: 5392-5531.
14 WHO. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel) final report. Circulation, 2002, 106: 3121-3143.
15 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议. 中华糖尿病杂志, 2004, 2(3): 156.
16 宋秀霞译. 国际糖尿病联盟代谢综合征全球共识定义. 中华糖尿病杂志, 2005, 13(3): 178-180.
17 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol, 1979, 237(3): E214-223.
18 Bergman RN. Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes, 1989, 38: 1512.
19 Steil GM, Murrary J, Bergman RN, et al. Repeatability of insulin sensitivity and glucose effectiveness from the minimal model: implication for study design. Diabetes, 1994, 43: 1365.
20 Steil GM, Volund A, Kahn SZ, et al. Reduced sampled number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes, 1992, 42: 250.
21 夏红, 李燕等. 减少样本数的最小模式对Ⅱ型糖尿病患者胰岛素抵抗的临床应用研究.中国糖尿病杂志, 1996, 4(1): 3-6.
22 Coates PA, Ollerton RL, Luzio SD, et al. Reduced sampled protocols in estimation of insulin sensitivity and glucose effectiveness using the minimal model in NIDDM. Diabetes, 1993, 42: 1635.
23 Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Clin Pract, 1990, 10: 167.
24 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-1 cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 1985, 28: 412-419.
25 Haffner S, Gonzaler C, Miettinen A, et al. A prospective analysis of the Homa model. the Mexico City Diabetes Study. Diabetes Care, 1996, 19: 1138-1141.
26 李光伟, 潘孝仁, Lillioja S, 等. 监测人群胰岛素敏感性的一项新指数. 中华内科杂志, 1993, 12(10): 656-660.
27 Caro JF, Clinical review 26. Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab. 1991, 73: 691-695.
28 丁荣蓉, 毛季萍. 2 型糖尿病大血管病变机理和糖尿病治疗. 医学与哲学 2004, 25(11): 41-42.
29 Mogul HR, Weinstein BI, Mogul DB, et al. Syndrome W: a new model of hyperinsulinemia, hypertension and midlife weight gain in healthy women with normal glucose tolerance. Heart Dis, 2002, 4(2): 78-85.
30 Wajchenberg BL, Giannella-Neto D, da-Silva ME, et al. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res, 2002, 34(11-12): 616-621.
31 Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med, 2001, 250: 105-120.
32 Mercado MM, McLenithan JC, Silver KD, et al. Genetics of insulin resistance. Curr Diab Rep, 2002, 2: 83-95.
33 Mi J, Law C, Zhang KL, et al. Effects of infant birthweight and maternal body mass index in pregnancy of components of the insulin resistance syndrome in China. Ann Intern Med,2000, 132: 253-260.
34 Vitaliano PP, Scanlan JM, Zhang J, et al. A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosom Med, 2002, 64(3): 418-435.
35 Raikkonen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence. Metabolism, 2002, 51(12): 1573-1577.
36 田成功, 邵加庆, 于镔. 瘦素: 胰岛素抵抗的独立危险因素. 中华内分泌代谢杂志, 2002, 18(3): 184-187.
37 刘超, 周红文. 瘦素和代谢综合征. 辽宁实用糖尿病杂志, 2002, 10(4): 2-4.
38 Assali AR, Ganor A, Beigel Y, et al. Insulin resistance in obesity: body weight or energy balance? J Endocrinol, 2001, 171(2): 293.
39 李东锋, 杨汉东, 杨波, 等. 代谢综合征患者血清瘦素与血脂、肥胖及胰岛素抵抗关系的研究. 实用医学杂志. 2005, 21(17): 1911-1913.
40 张俊清, 高研, 郭晓惠, 等. 肥胖青少年血清瘦素、胰岛素和胰岛素原水平的变化. 中华内科杂志, 2002, 41(4): 221-223.
41 Kondo H, Shimomura I, Katsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes, 2002, 51(7): 23-25.
42 Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 2001, 50(5): 1126.
43 Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med, 2005, 257: 167-175.
44 Yamauchi T, Oike Y, Kamon J, et al. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Net Genet, 2002, 30(2): 211.
45 Berg AH, Combs TP, Schrere PE, et al. adponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab, 2001, 13(20): 84.
46 张艳芳, 吴汉妮. 抵抗素与胰岛素抵抗. 国外医学分子生物学分册, 2003, 25(5): 297 299.
47 鲁瑾, 邹大进, 张家庆. 肿瘤坏死因子-α 致胰岛素抵抗. 中国病理生理杂志, 1999, 15(12): 1146-1148.
48 顾鸣宇, 盛正妍. 胰岛素抵抗与脂肪肝. 国外医学内分泌分册, 2003, 23(增刊): 32-33.
49 余丹箐, 高鑫, 赵耐青, 等. 肥胖患者血清 C-反应蛋白水平变化与代谢综合征的关系. 复旦学报(医学版), 2002, 29(1): 45-49.
50 韩萍, 何冰, 崔力, 等. C 反应蛋白和白细胞介素 6 以及肿瘤坏死因子 α 对 2 型糖尿病和代谢综合征发生的影响. 中国糖尿病杂志, 2003, 11(1): 57-58.
51 杨郁, 李昌臣. 炎症与代谢综合征. 实用糖尿病杂志, 2005, 1(2): 13-15.
52 孙东升, 张继业. 纤溶酶原激活物抑制剂-1 与代谢综合征. 心血管病学进展, 2001,22(5): 303-304.
53 宁光, 陈家伦. 胰岛素抵抗状态下 HepG2 细胞纤维蛋白溶解酶原激活物抑制物-1 基因表达. 中华内分泌代谢杂志, 2000, 16(4): 239-242.
54 Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes, 2004, 53: 336-346.
55 朱旅云, 刘坤申. 胰岛素抵抗与内皮功能障碍. 国外医学内分泌分册, 2002, 22(5): 319-320 .
56 余叶容, 李宏亮, 喻红玲, 等. 单纯性肥胖患者胰岛素抵抗与内皮依赖性血管舒张动能的研究. 中华医学杂志, 2003, 83(17): 1467-1470.
57 刘金来, 郝宝顺, 朱承明, 等. 代谢综合征患者危险因素聚集对血管内皮功能的影响. 中国临床康复, 2005, 9(3): 63-65.
58 朱族云, 刘坤申. 胰岛素抵抗与内皮细胞障碍. 国外医学内分泌学分册, 2002, 22(9): 319-320.
59 漆泓, 孙明, 周宏研. MS 患者空腹血清游离脂肪酸水平与胰岛素抵抗的关系. 临床内科杂志, 2003, 20(7): 353-355.
60 Vetter R, Lombardi AM, Fabris R, et al. Substrate competition and insulin action in animal models. Int J Obes Relat metab Disord, 2000, 24[Suppl 2]: S22-24.
61 Whorwood CB, Donovan SJ, Flanagan D, et al. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes, 2002, 51 (4): 1066-1075.
62 Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science, 2001, 294(5549): 2166-2170.
63 Terzolo M, Pia A, Ali A, et al. Adrenal incident aloma: a new cause of themetabolic syndrome. J Clin End Ocrinol Metab, 2002, 87(3): 998-1003.
64 Hjemdahl P. Stress and the metabolic syndrome: an interesting but enigmatic association. Circulation, 2002, 106: 2634-2636.
65 纪立农. 代谢综合征与 2 型糖尿病. 国外医学内分泌学分册, 2002, 22(5): 281-282.
66 Eckle RH, Grundy SM, Zimmet PZ. The metabolism syndrome. Lancet, 2005, 365: 1415-1428.
67 Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol, 1999, 84: 11-14.
68 Despres JP, Beno it L, Pascale M, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med, 1996, 334: 952-957.
69 Jia WP, Lu JX, Xiang KS, et al. Prediction of abdominal visceral obesity from body mass index, waist circumference and waist-hip ratio in Chinese adults: receiver operating characteristic curves analysis. Biomed Environ Sci, 2003, 16: 206-211.
70 洪洁, 顾卫琼, 张翼飞, 等. 糖耐量不同的代谢综合征患者胰岛素抵抗和胰岛 β 细胞1 相胰岛素分泌功能的研究. 中华医学杂志, 2003, 83(22): 1952-1956.
71 Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension, 1992, 19: 403-409.
72 Haffner SM, Ferrannini E, Hazuda HP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension, 1992, 20: 38-43.
73 Isomaa B, Aimgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24: 683-689.
74 窦相峰, 张红叶, 孙凯, 等. 中国汉族人代谢综合征与脑卒中密切相关. 中华医学杂志, 2004, 84: 539-542.
75 徐焱成. 胰岛素抵抗综合征的研究近况. 医学新知杂志, 2004, 14(2): 78-81.
76 范建高. 非酒精性脂肪肝与代谢综合征. 国外医学内分泌学分册, 2002, 22 (5): 284.
77 Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med, 1999, 107: 450-455.
78 Sanyal AJ, Campbell-sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120: 1183-1192.
79 罗瑞华, 李晔, 黄学文. 非酒精性脂肪肝与代谢综合征的关系探讨. 中国临床医学, 2004, 11(5): 742-744.
80 Eugene C. The relationship between systemic hypertension and obstructive sleep apnea facts and theory. Am J Med, 1995, 98(10): 118.
81 肖丹, 康健, 王秋月, 等. 阻塞性睡眠呼吸暂停患者睡眠时高血压的发生. 中华结核和呼吸杂志, 1998, 21(11): 654.
82 慈书平, 江时森. 睡眠呼吸暂停与多系统器官损害研究进展. 中华结核和呼吸杂志, 1997, 20(1): 39.
83 慈书平, 范玮, 刘树森, 等. 老年人睡眠呼吸暂停综合征与糖代谢紊乱. 中国老年学杂志, 1995, 15(4): 20.
84 Parish JM, Shepar JW. Cardiovascular effects of sleep disorders. Chest, 1990, 97(5): 1220.
85 路影, 蓝红林, 马维红. 老年 2 型糖尿病患者微量白蛋白尿与胰岛素抵抗的关系. 中华老年医学杂志, 1999, 18(2): 77-79.
86 路影, 尹友生, 蓝红林, 等. 血压正常的 2 型糖尿病患者微量白蛋白尿与胰岛素抵抗的关系. 中华肾脏病杂志, 1999, 15(2): 116-117.
87 Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al. Microalbum inuria is associated with insulin resistance in nodiabetic subjects: the insulin resistance athero sclerosis study. Diabetes, 1998, 47(5): 793-800.
88 Catalano C, Muscelli E, Quinones GA, et al. Effect of insulin on systemic and renal handing of album in nondiabetic and NIDDM subjects. Diabetes, 1997, 46(5): 868-875.
89 Spangler JG, Konen JC. Hypertension, hyperlipodemia, and abdominal obesity and the development of microalbuminuria in patients with non-insulin-dependent diabetes mellitus. J Am Board Fam Pract, 1996, 9: 1-6.
90 Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens. 1999, 17(7): 869-872.
91 Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults. Ann Epidemiol, 1998, 8(4): 250-261.
92 杜鹃. 有氧运动改善胰岛素抵抗综合征的研究进展. 国外医学内分泌学分册, 2004, 24(5): 347-349.
93 Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol, 2004, 93: 136-141.
94 Pyorala K, Ballantyne C, Lee M, et al. Reduction of coronary events by simvastatin in non–diabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analysis of the Scandinavian Simvastat in Survival Study. Diabetes, 2003, 52: A19.
95 Rubins H B, Robins S J, Collins D, et al. Diabetes, plasmainsulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VAHIT). Arch Int Med, 2002, 162: 2597-2604.
96 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342(3): 145-153.
97 American Diabetes Association. Implication of the United Kingdom Prospective Diabetes Study. Diabetes care, 1998, 21: 2180-2185.
98 Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome, systematic review and meta-analysis. BMJ, 2003, 327: 951-956.
99 郭冀珍, 龚艳春, 章建梁, 等. 高血压病伴代谢综合征患者 463 例的干预治疗研究. 中华心血管病杂志. 2005, 33(2): 132-136.
100 王志国, 杨晔, 高连如, 等. 行为干预加二甲双胍对代谢综合征生物学和血生化指标的影响. 中国临床康复, 2004, 8(18): 3528-3529.
101 Stephen Smith. 罗格列酮改善胰岛素抵抗和 β 细胞功能及对心血管的潜在保护作用. 国外医学内分泌学分册, 2002, 22(5): 284-286.
102 Grundy SM, Brewer B, Cleeman JI, et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conferenceon Scientific Issue Related to Definition. Circulation, 2004, 109: 433-438.
1 宋秀霞译. 国际糖尿病联盟代谢综合征全球共识定义. 中华糖尿病杂志, 2005, 13(3): 178-180.
2 吕仁和, 张法荣, 高彦彬, 等. 消渴病(糖尿病)的分期辨证与疗效评价标准. 中国医药学报, 1993, 8(3): 50-56.
3 郑筱萸. 中药新药临床研究指导原则(试行). 北京: 中国医药科技出版社, 2002, 85-89, 233-237, 383-384.
4 李光伟, 潘孝仁, Lillioja S, 等. 监测人群胰岛素敏感性的一项新指数. 中华内科杂志, 1993, 12(10): 656-660.
5 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-1 cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 1985, 28: 412-419.
6 Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial ysfunction in children and adults at risk of atherosclerosis. Lancet, 1992, 340: 1111-1117.
7 褚熙, 吕学成, 王艳清, 等. 代谢综合征患者肱动脉血管顺应性的超声研究. 中国中西医结合影像学杂志, 2005, 3(3): 178-180.
8 顾东风, Reynolds K, 杨文杰, 等. 中国成年人代谢综合征的患病率. 中华糖尿病杂志, 2005, 13(3): 181-186.
9 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议. 中华糖尿病杂志, 2004, 12(3): 156-161.
10 《中国糖尿病防治指南》编写组. 中国糖尿病防治指南. 北京: 北京大学医学出版社, 2004 年 1 月第一版, 46-47.
11 徐晖. 泽泻药理作用研究进展. 湖南中医杂志, 2004, 20(3): 77-78.
12 张林丽. 茵陈的药理研究和临床应用近况. 广酉医学, 2003, 25(11): 2185-2186.
13 闫瑾. 丹参及其有效成分的药理作用研究述略. 中医药学刊, 200, 22(9): 1725-1726.
14 邢淑丽, 黄文政, 郑君英. 中药鬼箭羽的临床和实验研究进展. 吉林中医药, 2005, 25(11): 62-63.
15 余园媛, 王伯初, 彭亮, 等. 黄连的药理研究进展. 重庆大学学报(自然科学版), 2006, 29(2): 107-111.
16 刘凯, 郑海生. 大黄酸的药理作用研究述略. 中医药学刊, 2004, 22(9): 1732-1734.
17 刘俊芳, 朱建华. 内皮功能障碍、炎症与动脉粥样硬化. 浙江医学, 2005, 27(11): 875-879.
18 夏菲. 胰岛素抵抗与凝血纤溶系统功能异常. 国外医学生理病理科学与临床分册, 2005, 25(3): 221-222
19 杨义生, 洪洁, 顾卫琼, 等. 脂肪组织的分泌功能与代谢综合征. 国外医学内分泌学分册. 2004, 24(3): 156-159.
20 张运, 张 梅, 陈文强, 等. 易损斑块的认识与研究进展. 心脏病学实践 2004-规范化治疗.北京: 人民卫生出版社, 2004: 233-245.
21 Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med, 1994, 331: 417- 424.
22 李英兰, 滕长青. 同型半胱氨酸与缺血性心脑血管病关系的研究进展. 中国老年学杂志, 2003, 9(23): 26.
23 Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res, 2001, 89: 763- 771.
24 王宏宇, 胡大一. 血管内皮功能检测的临床应用. 中国医刊, 2003, 38(3): 57-59.
1 曹廷兵, 闫振成, 沈成义, 等. 代谢综合征大鼠模型的建立及其相关基因表达变化的研究. 解放军医学杂志, 2005, 30(8): 702-705.
2 程海波, 司晓晨, 尚文斌, 等. 高脂饲料和高果糖餐分别诱导胰岛素抵抗大鼠模型的胰岛素敏感性. 中医临床康复, 2006, 10(7): 121-123.
3 Storlien LH, Pan DA, Kusunoki Metal. Effects of benfluorex on in vivo patterns of insulin resistance induced by diet rich in fat or fructose. Diabetes/ Metabolism Rev, 1993, 9(suppl 1): 65S-72S.
4 Fueger PT, Bracy DP, Malabanan CM, et al. Hexokinase Ⅱ over expression improves exercise-stimulated but not insulin-stimulated muscle glucose uptake in high-fat-fed C57BL/6J mice. Diabetes, 2004, 53: 306-314.
5 Youngren JF, Paik J, Barnard RJ. Impaired insulin-receptor autophosphorylation is a nearly defect in fat-fed, insulin-resistant rats. J Appl Physiol, 2001, 91: 2240-2247.
6 Mithieux G, Guignot L, Bordet JC, et al. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high–fat diet. Diabetes, 2002, 51: 139-143.
7 Chan CB, Deleo D, Joseph JW, et al. Increased uncoupling protein-2 levels in β-cells are associated with impaired glucose-stimulated insulin secretion. Diabetes, 2001, 50: 1302-1310.
8 Tremblay F, Lavigne C, Jacques H, et al. Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinase C(ξ/λ) activities. Diabetes, 2001, 50: 1901-1910.
9 Kim C H, Youn J H, Park J Y, et al. Effects of high-fat diet and exercise training on intracellular glucose metabolism in rats. Am J Physiol Endocrinol Metab, 2000, 278: E977-E984.
10 Perriello G, Misericordia P, Volpi E, et al. Contribution of obesity to insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1995, 80: 2464-2469.
1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001, 285: 2486-2497.
2 Ross R. Cell biology of atherosclerosis. Ann Rev Physiol, 1995, 57: 791-795.
3 Feata A, D’Agostino RJr,Howard G, et al. Chronic subclinicial inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study(IRAS). Circulation, 2000, 102: 42-47.
4 Yudhin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in health subjects: association with obesity, insulin resistance, and endothelial dysfunction: a potential role of cytokines origination from adipose tissue? Atheroscler Thromb Vase Biol, 1999, 19: 972-978.
5 秦海春, 郭强, 王芸. 肝硬化患者 TNF-α, IL-6, HA, CIV 水平测定的临床意义. 中国现代医学杂志, 2002, 12(1): 36-37.
6 信涛, 徐玉清, 姜秋颖, 等. TNF-α 和 Bcl-2 在大肠癌中的表达及意义. 中国现代医学杂志, 2003, 13(13): 87-89.
7 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: director role in obesity-linked insulin resistance. Science, 1993, 259: 87-91.
8 Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-α: in human obesity and insulin resistance. J Clin Invest, 1995, 95(5): 2409-2415.
9 Fried SK, Zechner R. Cachection/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis and activity. J Lipid Res, 1989, 30: 1917-1923.
10 Kern PA, Saghizadeh M, Ong JM, et al. The expression of TNF-α in human adipose tissue regulation by obesity, weight loss and relationship to lipoprotein lipase. J Clin Invest, 1995, 95: 2111-2119.
11 Prins JB, Niesler CV, Winterford CM, et al. Tumor necrosis factor-α induced apotosis of human adipose cell. Diabetes, 1997, 46: 1939-1944.
1 Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol, 2002, 13: 51-59.
2 Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules. Circulation, 1999, 100(25): 2473-2476.
3 Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol, 2003, 23: 85-89.
4 Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res, 2000, 32: 47-50.
5 Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem, 2002, 277(40): 37487- 37491.
6 Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE deficient mice from atherosclerosis. J Biol Chem, 2003, 278(4): 2461-2468.
7 Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E deficient mice. Circulation, 2002, 106: 2767-2670.
8 Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 2002, 105(24): 2893-2898.
9 Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun, 1999, 257: 79-83.
10 Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001, 86: 1930-1935.
11 梁晓萍, 韩全水, 文锦丽, 等. 超重和肥胖人群高血压病的患病率及血清脂联素水平的变化. 中华心血管病杂志, 2006, 34(1): 41-44.
12 陆俊茜, 贾伟平, 王遂军, 等. 血清脂联素水平降低是代谢综合征的特征性标志. 上海医学, 2005, 28(8): 650-652.
13 Yang WS, Lee WJ, Funahashi T, et al. Weight induction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clini Endocrinol Metab, 2001, 86: 3815-3819.
14 Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol, 2000, 20: 1595-1599.
15 Lihn AS, Ostergard T, Nyholm B, et al. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab, 2003, 284: 443-448.
16 Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 2001, 50 (5): 1126-1133.